Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Registration Number
- NCT01209741
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Subject is in good health
- Subject is a nonsmoker
- Subject is willing to comply with the study restrictions
Exclusion Criteria
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- Subject has a history of cancer
- Subject is a nursing mother
- Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 telcagepant potassium MK-0974 12MoRT 2 MK-0974 5Mo5C MK-0974 5Mo5C 3 MK-0974 12Mo5C MK-0974 12Mo5C
- Primary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations Through 48 hours postdose Peak plasma concentration (Cmax) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations Through 48 hours postdose
- Secondary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations Through 48 hours postdose Peak plasma concentration (Cmax) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations Through 48 hours postdose